About Careers MedBlog Contact us

Drug Anastrazole Boosts Long-term Survival After Breast Cancer in Postmenopausal Women

by Bidita Debnath on May 31, 2015 at 1:31 PM
Font : A-A+

Drug Anastrazole Boosts Long-term Survival After Breast Cancer in Postmenopausal Women

After a diagnosis of localized breast cancer, women are often prescribed tamoxifen for five years to help prevent a recurrence, but researchers said that another drug, anastrazole, may work better.

The federally funded phase III study involved more than 3,100 postmenopausal women with a kind of breast cancer known as ductal carcinoma in situ, which was treated by removing the cancerous lump followed by a radiation regimen.


Some women were then randomly assigned to receive tamoxifen and others anastrazole.

After 10 years, 93.5% of women in the anastrazole group were living breast cancer-free, compared to 89.2% in the tamoxifen group, according to the first major study to compare the two treatments, released at the American Society of Clinical Oncology conference in Chicago.

"The good news is tamoxifen and anastrazole are both very effective, but it seems that women have better chances of staying well with anastrazole," said lead study author Richard Margolese, a professor of surgical oncology at The Jewish General Hospital, McGill University in Montreal, Canada.

"Women should also consider differences in side effects when discussing treatment options with their doctors."

The drugs were similarly tolerated by patients with few side effects, though anastrazole tends to speed up osteoporosis and put women at higher risk of bone fracture, while tamoxifen has been associated with higher rates of uterine cancer.

The differences in these complications were not statistically significant when the two drugs were compared, researcher said.

Both drugs block estrogen -- which can fuel the growth of hormone receptor-positive breast cancer -- but in different ways.

Tamoxifen blocks the access of estrogen to the cancer cells, while anastrazole is an aromatase inhibitor which suppresses the manufacturing of estrogen.

Women diagnosed with DCIS face an increased risk of getting invasive breast cancer later in life, but deaths from DCIS are uncommon after the tumor is removed followed by radiation therapy.

The patients were followed for an average of 8.6 years, during which time 114 breast cancers were detected in the tamoxifen group compared to 84 in the anastrazole group.

Eight women died of breast cancer in the tamoxifen group and five in the anastrazole group.

The 10-year overall survival rates were comparable in the two groups (92.5% for anastrazole and 92.1% for tamoxifen).

When looking at the subgroup of women over 60, however, researchers also found that anastrazole may not be superior to tamoxifen.

"Women with DCIS already have several great treatment options, and now they have one more," said ASCO expert Don Dizon of Massachusetts General Hospital.

"Aromatase inhibitors offer important advantages, but patients and their doctors should still consider the full range of options, including tamoxifen or even foregoing adjuvant treatment, as every approach carries its own risks and benefits."

Source: AFP


Recommended Reading

Latest Women Health News

 Pregnancy Loss More Likely to Occur in Slowly Developing Embryos
Does embryo growth affect miscarriage chances in pregnancies? Yes, embryonic development is delayed in pregnancies ending in a miscarriage compared to ongoing pregnancies.
Healthy at Every Age: Essential Health Tests for Women Over 30!
Don't let a full heart fool you - it's essential to be aware of your age and the challenges it presents in life as per a new study.
Female Genital Tuberculosis Needs Quick Intervention
In 90% of women with female genital tuberculosis condition, the fallopian tubes are affected. In around 70% uterine endometrium is affected.
Road Accidents During Pregnancy Increase the Risk of Birth Complications
Women involved in motor vehicle crashes during pregnancy were at increased risk of various adverse pregnancy outcomes, especially while riding scooters.
Beware Women! Shift Work can Make You Frail
Are shift works bad for women's health? Yes, Women who are working rotating shifts are more likely to be frail.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Drug Anastrazole Boosts Long-term Survival After Breast Cancer in Postmenopausal Women Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests